Publication Name	World Journal of Hepatology
Manuscript ID	15661
Country	Australia

Received	2014-12-02 10:41
Peer-Review Started	2014-12-04 08:26
To Make the First Decision	2015-01-08 14:05
Return for Revision	2015-01-12 20:07
Revised	2015-01-16 08:38
Second Decision	2015-02-10 16:24
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-02-12 15:03
Articles in Press	2015-02-12 15:04
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-04-23 18:01
Publish the Manuscript Online	2015-05-13 10:06

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure
Manuscript Source	Invited Manuscript
All Author List	Venessa Pattullo
Funding Agency and Grant Number
Corresponding Author	Dr. Venessa Pattullo, MBBS, FRACP, PhD, Department of Gastroenterology, Royal North Shore Hospital, 4B Acute Services Building, St Leonards NSW 2065, Sydney, Australia. venessa.pattullo@sydney.edu.au
Key Words	Immunosuppression; Hepatitis B; Hepatitis B virus reactivation; Prophylaxis; Lamivudine; Chemotherapy; Entecavir; Tenofovir; Rituximab
Core Tip	Hepatitis B virus reactivation is a potentially fatal but preventable complication of chemotherapy and immunosuppression. Both chronically infected [hepatitis B surface antigen (HBsAg) positive] and previously exposed (HBsAg negative/anti-HBc positive) patients are susceptible, the risk observed to be strongly associated with the potency of the immunosuppressive drug regime and the baseline virological status. The knowledge gaps that require further investigation in the optimal management of this phenomenon are discussed in this review. Recom-mendations regarding screening, monitoring and the role of antiviral prophylaxis are outlined with reference to current international associations’ guidelines and the best available evidence to date.
Publish Date	2015-05-13 10:06
Citation	Pattullo V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World J Hepatol 2015; 7(7): 954-967
URL	http://www.wjgnet.com/1948-5182/full/v7/i7/954.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i7.954

Full Article (PDF)	WJH-7-954.pdf
Full Article (Word)	WJH-7-954.doc
Manuscript File	15661-Review.docx
Answering Reviewers	15661-Answering reviewers.pdf
Audio Core Tip	15661-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	15661-Conflict-of-interest statement.pdf
Copyright License Agreement	15661-Copyright assignment.pdf
Peer-review Report	15661-Peer-review(s).pdf
Scientific Misconduct Check	15661-Scientific misconduct check.pdf
Scientific Editor Work List	15661-Scientific editor work list.pdf